866-997-4948(US-Canada Toll Free)

HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 60 Pages

HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016

Summary

Global Markets Directs, HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016, provides in depth analysis on HIV 1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV 1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for HIV 1 Integrase (EC 2.7.7.)
- The report reviews HIV 1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
- The report assesses HIV 1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to HIV 1 Integrase (EC 2.7.7.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for HIV 1 Integrase (EC 2.7.7.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding HIV 1 Integrase (EC 2.7.7.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
HIV 1 Integrase (EC 2.7.7.) Overview 7
Therapeutics Development 8
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development 8
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area 9
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Indication 10
HIV 1 Integrase (EC 2.7.7.) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Companies 13
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes 15
HIV 1 Integrase (EC 2.7.7.) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
HIV 1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development 23
Critical Outcome Technologies Inc 23
Gilead Sciences Inc 24
Merck & Co Inc 25
TGV-Laboratories 26
ViiV Healthcare Ltd 27
HIV 1 Integrase (EC 2.7.7.) - Drug Profiles 28
(bictegravir sodium +emtricitabine + tenofovir alafenamide) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
cabotegravir sodium - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
cabotegravir sodium + rilpivirine hydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
elvitegravir - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
M-522 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
M-532 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
MK-2048 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecule to Inhibit Integrase for HIV - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
T-169 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
HIV 1 Integrase (EC 2.7.7.) - Dormant Projects 46
HIV 1 Integrase (EC 2.7.7.) - Discontinued Products 47
HIV 1 Integrase (EC 2.7.7.) - Featured News & Press Releases 48
Nov 18, 2016: ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen 48
Jul 26, 2016: SMILE Trial Launch - investigating a potentially lower toxicity, simplified treatment regimen for HIV infected children 48
Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir 49
Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment 50
Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy 51
May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy 52
Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment 52
Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys 53
Apr 21, 2014: Gilead Sciences New Drug Applications for Elvitegravir for HIV Therapy Accepted by U.S. FDA 54
Nov 18, 2013: European Commission Approves Gileads Vitekta, an Integrase Inhibitor for the Treatment of HIV-1 Infection 54
Sep 19, 2013: Gilead Sciences Receives CHMP Positive Opinion For Vitekta For Treatment Of Human Immunodeficiency Virus-1 Infection In Adults 55
Jul 03, 2013: Monthly Injections With GSK And J&J's Combination Therapy Sustained Drug Levels In Blood To Control HIV, Study Shows 56
Apr 29, 2013: Gilead Sciences Receives Complete Response Letter From FDA For Elvitegravir 56
May 20, 2010: Critical Outcome Technologies Inc. Discovers Novel Scaffolds For Inhibiting HIV Integrase 57
Apr 13, 2010: Critical Outcome Technologies Inc. Provides Update On HIV-1 Integrase Co-Development Program 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Critical Outcome Technologies Inc, H2 2016 23
Pipeline by Gilead Sciences Inc, H2 2016 24
Pipeline by Merck & Co Inc, H2 2016 25
Pipeline by TGV-Laboratories, H2 2016 26
Pipeline by ViiV Healthcare Ltd, H2 2016 27
Dormant Projects, H2 2016 46
Discontinued Products, H2 2016 47

List of Figures
Number of Products under Development for, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *